Glucose-6-phosphate dehydrogenase deficiency in retinal vein occlusion

Investigative Ophthalmology and Visual Science

Volumn 48, Issue 6, 2007, Pages 2747-2752

  Pinna, Antonio ^a   Carru, Ciriaco ^a   Solinas, Giuliana ^a   Zinellu, Angelo ^a   Carta, Francesco ^a  

^a UNIVERSITY OF SASSARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; ENZYME BLOOD LEVEL; FEMALE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INTRAOCULAR PRESSURE; ITALY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREVALENCE; PRIORITY JOURNAL; SEX RATIO; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; VISUAL ACUITY; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CEREBROVASCULAR DISEASE; ENZYMOLOGY; ERYTHROCYTE MEMBRANE; MIDDLE AGED; MORTALITY; RETINA VEIN OCCLUSION; RISK FACTOR;

AGED; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CEREBROVASCULAR DISORDERS; ERYTHROCYTE MEMBRANE; FEMALE; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; HUMANS; ITALY; MALE; MIDDLE AGED; RETINAL VEIN OCCLUSION; RISK FACTORS;

EID: 34347206389     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.06-1064     Document Type: Article

References (36)

1. Clarkson JG. Central retinal vein occlusion. In: Ryan SJ, ed.: Medical Retina. 3rd ed. St. Louis: Mosby Inc., 2001:1368-1375; Retina. Vol. 2.
2. Fekrat S, Finkelstein D. Branch retinal vein occlusion. In: Ryan SJ, ed. Medical retina. 3rd ed. St. Louis: Mosby Inc., 2001:1376-1381; Retina. Vol. 2.
3. Cahill MT, Stinnett SS, Fekrat S. Meta-analysis of plasma homocysteine, serum folate, serum vitamin B(12), and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease. Am J Ophthalmol. 2003;136:1136-1150.
4. Cocco P, Todde P, Fornera S, Manca MB, Manca M, Sias AR. Mortality in a cohort of men expressing the glucose-6-phosphate dehydrogenase deficiency. Blood. 1998;91:706-709.
5. Kletzien RF, Harris PKW, Foellmi LA. Glucose-6-phosphate dehydrogenase: a "housekeeping" enzyme subject to tissue-specific regulation by hormones, nutrients, and oxidant stress. FASEB J. 1994;8:174-181.
6. Beutler E. G6PD deficiency. Blood. 1994;84:3613-3636.
7. Batetta B, Bonatesta RR, Sanna F, et al. Cell growth and cholesterol metabolism in human glucose-6-phosphate dehydrogenase deficient lymphomononuclear cells. Cell Prolif. 2002;35:143-154.
8. Maida A, Pettinato S, Bo G. Clinical manifestations of favism and G6PD deficiency: epidemiological survey in the province of Sassari (Sardinia, Italy). Haematologica. 1973;58:1265-1282.
9. Martinez di Montemuros F, Dotti C, Tavazzi D, Fiorelli G, Cappellini MD. Molecular heterogeneity of glucose-6-phosphate dehydrogenase (G6PD) variants in Italy. Haematologica. 1997;82:440-445.
10. Beutler E, Blume KG, Kaplan JC, Lohr GW, Ramot B, Valentine WN. International Committee for Standardization in Haematology: recommended screening test for glucose-6-phosphate dehydrogenase (G6PD) deficiency. Br J Haematol. 1979;43:465-467.
11. Kurdi-Haidar B, Mason PJ, Berrebi A, et al. Origin and spread of the glucose-6-phosphate dehydrogenase variant (G6PD-Mediterranean) in the Middle East. Am J Hum Genet. 1990;47:1013-1019.
12. Clayton D, Hills M, eds. Statistical Models in Epidemiology. Oxford, UK: Oxford University Press, 1993.
13. The Eye Disease Case-Control Study Group. Risk factors for central retinal vein occlusion. Arch Ophthalmol. 1996;114:545-554.
14. The Eye Disease Case-Control Study Group. Risk factors for branch retinal vein occlusion. Am J Ophthalmol. 1993;116:286-296.
15. Meloni T, Carta F, Forteleoni G, Carta A, Ena F, Meloni GF. Glucose 6-phosphate dehydrogenase deficiency and cataract of patients in Northern Sardinia. Am J Ophthalmol. 1990;110:661-664.
16. Pinna A, Carru C, Zinellu A, Dore S, Deiana L, Carta F. Plasma homocysteine and cysteine levels in retinal vein occlusion. Invest Ophthalmol Vis Sci. 2006;47:4067-4071.
17. McGimpsey SJ, Woodside JV, Bamford L, et al. Retinal vein occlusion, homocysteine, and methylene tetrahydrofolate reductase genotype. Invest Ophthalmol Vis Sci. 2005;46:4712-4716.
18. Kumar B, Yu D, Morgan WH, Barry CJ, Constable IJ, MacAllister IL. The distribution of angioarchitectural changes within the vicinity of the arteriovenous crossing in branch retinal vein occlusion. Ophthalmology. 1998;105:424-427.
19. Casu A, Pascutto C, Bernardinelli L, Songini M. Type 1 diabetes among Sardinian children is increasing. Diabetes Care. 2004;27:1623-1629.
20. Ministero della Salute. Diabete: una patologia in netto aumento. Available at: http://www.ministerosalute.it/dettaglio/pdPrimoPiano.jsp?id= 107&sub=1&lang=it/. Accessed February 11, 2007.
21. WHO Working Group. Glucose-6-phosphate dehydrogenase deficiency. Bull World Health Organ. 1989;67:601-611.
22. Ruwende C, Hill A. Glucose-6-phosphate dehydrogenase deficiency and malaria. J Mol Med. 1998;76:581-588.
23. Siniscalco M, Bernini L, Latte B, Motulski AG. Favism and thalassemia and their relationship to malaria. Nature. 1961;190:1179-1180.
24. Luzzatto L, Notaro R. Malaria: protecting against bad air. Science. 2001;293:442-443.
25. Rao KN. The significance of cholesterol biosynthesis pathway in cell growth and carcinogenesis (review). Anticancer Res. 1995;15:309-314.
26. Cocco P. Does G6PD deficiency protect against cancer? - a critical review. J Epidemiol Commun Health. 1987;41:89-93.
27. Wallace MN. NADPH diaphorase activity in activated astrocytes representing inducible nitric oxide synthase. Methods Enzymol 1996:268:497-503.
28. Li H, Poulos TL. Structure-function studies on nitric oxide synthases. J Inorg Biochem. 2005;99:293-305.
29. Wink DA, Nims RW, Darbyshire JF, et al. Reaction kinetics for nitrosation of cysteine and glutathione in aerobic nitric oxide solutions at neutral pH. Insights into the fate and physiological effects of intermediates generated in the NO/O2 reaction. Chem Res Toxicol. 1994;7:519-525.
30. Myers PR, Minor RL, Guerra R, Bates JN, Harrison DG. Vasorelaxant properties of the endothelium-derived relaxing factor more closely resemble S-nitrosocysteine than nitric oxide. Nature. 1990;345:161-163.
31. Lewis SJ, Hashmi-Hill MP, Owen JR, Sandock K, Robertson TP, Bates JN. The vasodilator potency of the endothelium-derived relaxing factor, L-S-nitrosocysteine, is impaired in conscious spontaneously hypertensive rats. Vasc Pharmacol. 2006;44:476-490.
32. Wink DA, Hanbauer I, Krishna MC, DeGraff W, Gamson J, Mitchell JB. Nitric oxide protects against cellular damage and cytotoxicity from reactive oxygen species. Proc Natl Acad Sci USA. 1993;90:9813-9817.
33. Chang CC, Liao YS, Lin YL, Chen RM. Nitric oxide protects osteoblasts from oxidative stress-induced apoptotic insults via a mitochondria-dependent mechanism. J Orthop Res. 2006;24:1917-1925.
34. Hogg N, Kalyanaraman B, Joseph J, Struck A, Parthasarathy S. Inhibition of low-density lipoprotein oxidation by nitric oxide: potential role in atherogenesis. FEBS Lett. 1993;334:170-174.
35. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43:109-142.
36. Moncada S, Higgs EA. The discovery of nitric oxide and its role in vascular biology. Br J Pharmacol. 2006;147(suppl 1):S193-S201.